Study title: A randomized, double-blind, parallel group, placebo-controlled, four-week efficacy and safety evaluation of Nasacort AQ 110 μg QD, followed by six-month open-label safety in children ages 2-5 years with perennial allergic rhinitis
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Respiratory Tract Diseases [C08] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: TRIAMCINOLONE | |||||
| ATC code: R01AD11 | |||||
| Document link: Triamcinolone Acetonide-Study 1.pdf | |||||
| Document date: 2011-09-23 | |||||
| Study number: XRG5029C_3502 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |